a2 National Symposium

‍Thomas Keane, MD, MBA, serves as assistant secretary for technology policy and national coordinator for health information technology. An engineer and physician, Dr. Keane previously served in the Office of the National Coordinator for Health Information Technology and as a senior advisor to the deputy secretary of the U.S. Department of Health and Human Services. Among other duties, he was an administrator of the COVID-19 Provider Relief Fund and led the development of the Agency for Healthcare Research and Quality (AHRQ) National Nursing Home COVID Action Network. Dr. Keane worked as a finite element software developer and enterprise software engineer prior to training as an interventional radiologist.

Nate Kline is The Wellness VC, a notably experienced executive, investor, and entrepreneur (four-time founder; Inc. 5000 honoree), boasting a multifaceted institutional finance career spanning more than two decades and a six-continent network. As an expert strategist and award-winning visionary, he’s added value across every business sector, company size, and stage, from fledgling startups to multinational conglomerates. Cistern Capital is a product of his personal passion for health and dedication to nurturing early-stage founders.

Prior to Cistern, Kline was a recognized thought leader in real estate investing as co-founder and chief investment officer of OneWall Communities. Previously, he led global consulting and financial training engagements with his own firm and partners after having spearheaded more than $20B of private equity and M&A transactions at Fortress and Merrill Lynch. Kline is a proud graduate of the Schreyer Honors College, Smeal College of Business, and Liberal Arts School at Pennsylvania State University, where he graduated with honors and two degrees in 4 years (BS in finance and BA in economics). While there, he co-founded the Nittany Lion Fund, marking a significant milestone as the first multimillion-dollar undergraduate student-managed hedge fund in the United States.

‍

Heather Koshinsky, PhD, serves as chair of the Bio+Health Track at SkyDeck, UC Berkeley’s premier startup accelerator supporting the intersection of biology, healthcare, and technology. She is also the vice president of innovation and brand integrity at LevGo, which develops and manufactures laboratory consumables in China, the European Union, and the United States, with global distribution. As a serial entrepreneur, she has previously co-founded four successful startups. Notably, she was the co-founder and CEO at Investigen, which receives royalty revenue for its IP, and co-founder and CSO at Eureka Genomics, which developed Eureka Genotyping that Thermo Fisher Scientific now sells internationally.

Dr. Koshinsky is a member of several incubators and accelerators located in the United States and Canada, and is/has been an advisor and/or board member to startups located in Poland, China, Taiwan, Philippines, India, the United Kingdom, Australia, the United States, and Canada, covering fields including novel and repurposed drugs, medical devices and diagnostics, vaccines, bioreactors, remote sensing in agriculture, low-light imaging chips, and big data analysis software for single-cell immunogenetics. A grant reviewer for over 20 years, an inventor on multiple patent families, and author of numerous papers, Dr. Koshinsky earned her PhD in microbiology from the University of Saskatchewan and certificates in business administration and marketing from UC Berkeley Extension.

Lyne Landry is a seasoned private equity investor and impact investment architect whose career spans continents and capital stacks. As co-founder of AgeTech Capital, she launched a next-generation investment firm focused on the trillion-dollar opportunity at the intersection of aging, AI, and purpose. Here, she is focused on building a firm that will reimagine aging as a source of resilience and value—deploying data-driven capital, scaling world-class solutions, and building a cross-sector movement that makes longevity work for all.

From leading $300M+ M&A transactions to structuring multi-fund platforms, she has consistently fused fiduciary discipline with a bold vision for systems change. Previously, at ThirdWay Partners, she helped build the firm from inception into a 45-person platform managing three funds. Known for building strong teams and operational foundations, Landry delivers strong financial returns pairing sharp investment strategies with a long-term view on how capital can accelerate impact at scale.

Mary Lazare, MS, MA, is the Principal Deputy Administrator for the Administration for Community Living (ACL), serving as the senior official performing the duties of the ACL Administrator and Assistant Secretary for Aging. She returned to the ACL in March 2025 following service from 2017–2021. Throughout a career focused on improving the health and well-being of people with disabilities and older adults, Lazare has led social services and healthcare systems in building partnerships across industries and all levels of government, modernizing system infrastructure and leveraging new technology, and creating opportunities for innovation in order to better meet the needs of the people they serve.

During her prior tenure at ACL, Lazare spearheaded key initiatives including an interagency task force focused on expanding employment opportunities for people with disabilities, a public-private partnership to prevent social isolation, and cross-sector collaboration to align healthcare and aging and disability services to improve health outcomes and reduce costs. Prior to joining ACL, she held leadership roles focused on home- and community-based services for older adults, including long-term care, at Lutheran Senior Services, Ascension Health, BJC HealthCare, and the Jewish Center for the Aged. Lazare holds a master’s degree in gerontology from Lindenwood University and a master’s in business administration and management from Maryville University of Saint Louis.

‍

Rose Maria Li, PhD, MBA, is the president and CEO of Rose Li and Associates, Inc. and co-principal investigator of the a2 Collective Coordinating Center. The U.S. Small Business Administration named Dr. Li the 2024 Small Business Person of the Year for Maryland. She was also honored in 2024 to receive small business leadership awards from the International Leadership Foundation and the Montgomery County Chamber of Commerce. Since 2016, she has served by appointment of the governor as chairperson of the Maryland Commission on Aging. By appointment of the governor, she also served on the Maryland State Board of Education (2016–2021).

Prior to founding RLA, Dr. Li served the National Institutes of Health (NIH) in leadership roles, including as senior policy advisor to the NIH Office of Extramural Research, special assistant for policy development with the NIH Office of Communication and Public Liaison, chief of the Population and Social Processes Branch within the National Institute on Aging Division of Behavioral and Social Research, and health scientist administrator with the Eunice Kennedy Shriver National Institute of Child Health and Human Development. She earned her BA in economics and MBA in finance and international business, both from the University of Chicago, and her PhD from Princeton University in public and international affairs, with a concentration in population policy. She completed postdoctoral research in demography, epidemiology, and economics of aging in Asia at the University of Michigan, Ann Arbor.

Shari Ling, MD, serves in the Center for Clinical Standards and Quality, responsible for assisting the Centers for Medicare & Medicaid Services (CMS) chief medical officer in the agency’s pursuit of higher quality health care, healthier populations, and lower cost through quality improvement. Her clinical focus and scientific interest are centered on the care of persons with dementia, multiple chronic conditions, and functional limitations. In addition to a clinician leadership role across CMS, Dr. Ling has represented CMS on several HHS committees and workgroups, including the National Alzheimer’s Project Act, Healthy People, Behavioral and Mental Health, Healthcare Associated Infections, the National Strategy to Combat Antimicrobial Resistance, and the Scientific Integrity Council. She also serves on the Visioning Committee for the National Institute on Aging (NIA)-funded Coordinating Center on the Economics of Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias: Prevention, Treatment, and Care led by the National Bureau of Economic Research.

Dr. Ling is an internist and rheumatologist who received her medical training at Georgetown University School of Medicine. Prior to her medical training, Dr. Ling earned her master’s degree in gerontology from the Leonard Davis School at the University of Southern California and subsequently served as the co-director of clinical services with the Andrus Older Adult Counseling Center. She completed geriatric medicine studies at Johns Hopkins University, where she remained on faculty for 5 years, after which she joined the Intramural Research Program as a staff clinician at NIA for 8 years focused on human aging and age-associated chronic diseases with attention to musculoskeletal conditions and mobility function. Dr. Ling serves as a part-time faculty member in the Division of Geriatric Medicine and Gerontology at Johns Hopkins University School of Medicine, and in the Division of Rheumatology, Allergy and Clinical Immunology at the University of Maryland. She volunteers at the Veterans Administration Medical Center in Baltimore.

‍

Stephen C. Liu, MBA, serves as managing director of strategic partnerships for the a2 Collective Coordinating Center. He has more than 25 years of experience leading go-to-market, digital infrastructure, strategic partnerships, and innovation initiatives across early-stage startups, global corporations, and nonprofit ventures. He helped establish the a2 Collective’s national brand, outreach strategy, and digital infrastructure from the ground up. He also has led business development and partnership with venture capital, accelerators, and industry partners (e.g., AWS Activate).

‍

Kat Mackenzie, MBA, MPH, is a relentless advocate for improving health outcomes and reducing financial burden through product innovation and consumer-focused design. For more than 25 years, she has led teams charged with solving complex challenges across the healthcare ecosystem—making care delivery more effective and less stressful for consumers. Grounded in her undergraduate studies in psychology at Colorado State University and graduate degrees (MBA and MPH) from Boston University, Mackenzie integrates behavioral economics, product strategy, and operational rigor to design, evaluate, and scale impactful solutions. Her experience spans behavioral health portfolio design in the UK, enterprise-wide utilization management transformation, product redesign, and growth strategies. She brings deep expertise across government funded healthcare programs (Medicare, TRICARE, etc.) and the payor and payvider landscape, including significant experience in reimbursement strategies and value-based care models. She has led the development and evaluation of innovative solutions designed to improve clinical outcomes, reduce chronic disease spend, and align financial incentives with sustainable health improvement. Her work emphasizes measurable impact—advancing quality, affordability, and long-term behavior change.

Mackenzie previously served as executive sponsor of Humana Military’s Innovation, Research & Development Lab, partnering with TRICARE and VA populations to pilot and scale forward-looking models of care. She most recently returned to support Medicare Advantage population health management at Humana, and currently leads the Discovery & Strategic Partnerships team, where she forges collaborations across consumers, payors, providers, academic institutions, startups, and the investment community to accelerate meaningful innovation. Known for connecting disparate ideas and cultivating strong, mission-driven teams, Mackenzie fosters environments where people are challenged to think beyond the current state and toward future-oriented healthcare design.

Jesse Mastrangelo, MSc, combines experience at the intersection of healthcare innovation, venture investment, and early-stage company development. As program manager at the Centre for Aging + Brain Health Innovation (CABHI), he leads their investment programs, supporting companies across health systems, longevity innovation, and life science. CABHI invests in healthtech, biotech, and fintech companies seeking to help older adults age with purpose, fulfillment, and dignity. As a core member of CABHI’s investment team, Mastrangelo has helped scale the organization’s investment portfolio to include over 100 companies as one of Canada's most active early-stage investors. He is also a lecturer in McMaster University's Faculty of Health Sciences, focusing on biomedical innovation.

Todd Jay Mitty, PhD, is founder and CEO of Silvernails Advisors LLC, where he advises and invests across a broad range of industries including blockchain, quantum computing, AI, sustainability, biotech, and energy. Dr. Mitty builds new ventures and leads existing businesses through imperative commercial and organizational transformations, like those introduced by rapidly emerging technologies.

Dr. Mitty is currently a board member at Lukka Inc., a global leader in enterprise data management for digital assets. He previously held executive, strategic transformation, risk management, and trading roles at LionTree, Credit Suisse, Bank of America Merrill Lynch, and Morgan Stanley. Dr. Mitty is also a conservation steward of agricultural land in New York’s Hudson Valley. He completed his PhD and MA in mechanical and aerospace engineering at Princeton University and his MS and BS in aeronautical engineering at Rensselaer Polytechnic Institute.

‍

Michael A. Morgan, PhD, is a project manager and emerging science and technology advisor at the U.S. Food and Drug Administration, where he works in the Office of Regulatory and Emerging Science, Office of the Chief Scientist, Office of the Commissioner. Currently, Dr. Morgan co-leads a team of 50 experts from across FDA developing Elsa, FDA’s first enterprise generative AI chatbot. To date, over 70% of staff have voluntarily used the tool. He also serves as a Commissioner's Office representative to the FDA AI Internal Council, FDA's final decision-making body for internal AI policies and guidelines.

Previously, Dr. Morgan served on detail at the Department of Health and Human Services (HHS), where he co-led the evaluation and analysis of over 500 HHS AI use cases and provided technical and business expertise to guide HHS leadership in acquiring cutting-edge AI solutions, platforms, and environments. Before his HHS detail, Dr. Morgan developed a novel AI horizon scanning tool at FDA to identify emerging health-related science and technologies and forecast their potential regulatory impact. The tool was adopted by the Office of Personnel Management.

Dr. Morgan completed a postdoctoral fellowship at the U.S. Naval Research Laboratory and received his graduate degree from the University of Maryland, College Park, and his undergraduate degree from Syracuse University, both in biochemistry.